Hospital Clinico Universidad de Chile

Santiago, RM 8380456

0 studies enrolling now · 2 studies all time

What they study most

HER2-Positive Primary Breast Cancer, Overactive Bladder, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine — Completed